SGI Acquires Febit's Synbio IP, Assets to 'Drastically Reduce' Gene Synthesis Cost | GenomeWeb

Synthetic Genomics said this week that it has purchased from Febit Holding GmbH the worldwide rights to three families of patents and patent applications related to gene synthesis.

As part of the deal, La Jolla, Calif.-based SGI also acquired all related know-how, equipment and technical support for the implementation of the technology, the firm said. Terms of the agreement were not discussed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.